/MTVA
MTVA Stock - MetaVia Inc.
Healthcare|BiotechnologyNASDAQ
$8.62+3.86%
+$0.32 (+3.86%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.22
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $9.48
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MTVA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.53 – $8.71
TARGET (TP)$9.91
STOP LOSS$7.93
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.29
52W High$30.25
52W Low$6.05
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-24,000 | $-7,000 | $-28,000 | $-72,000 | $-67,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-28,809,000 | $-15,886,000 | $-19,628,000 | $-15,298,000 | $-29,716,000 |
| Net Income | $-27,592,000 | $-12,470,000 | $-13,967,000 | $-15,284,000 | $-29,678,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-39.16 | $-27.06 | $-477.84 | $-1742.40 | $-4831.20 |
Company Overview
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$12
Average Target
↑ 39.2% Upside
Now
$12
Low
$12
Average
$12
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 4th 2025 | H.C. Wainwright | Resumed | Buy | $12 |
| December 30th 2024 | H.C. Wainwright | Initiation | Buy | $12 |
Earnings History & Surprises
MTVABeat Rate
44%
Last 9 quarters
Avg Surprise
-344.5%
EPS vs Estimate
Beats / Misses
4/5
Last 12 quarters
Latest EPS
$-1.54
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
-1219.2%
$-14.51vs$-1.10
Q3 24
-34.1%
$-1.85vs$-1.38
Q4 24
+24.7%
$-0.55vs$-0.73
Q4 24
No data
Q2 25
+36.8%
$-0.36vs$-0.57
Q3 25
+18.8%
$-0.26vs$-0.32
Q4 25
+46.2%
$-1.54vs$-2.86
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-2.08 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-2.86 | $-1.54 | +46.2% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.32 | $-0.26 | +18.8% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.57 | $-0.36 | +36.8% | ✓ BEAT |
Q4 2024 | Dec 31, 2024 | — | $-6.59 | — | — |
Q4 2024 | Nov 7, 2024 | $-0.73 | $-0.55 | +24.7% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-1.38 | $-1.85 | -34.1% | ✗ MISS |
Q1 2024 | Mar 31, 2024 | $-1.10 | $-14.51 | -1219.2% | ✗ MISS |
Q4 2023 | Dec 31, 2023 | — | $-11.51 | — | — |
Q3 2023 | Sep 30, 2023 | $-0.88 | $-8.27 | -840.2% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $-1.04 | $-1.60 | -53.5% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-0.48 | $-5.66 | -1079.6% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | — | $-19.12 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-308.25 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-327.06 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-284.68 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-485.32 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-410.02 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-470.54 | — | — |
Latest News
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 5, 2025, 12:50 AM
MetaVia announces 1-for-11 reverse stock split; shares slip over 15%
📉 NegativeSeeking Alpha•Dec 2, 2025, 03:04 PM
MetaVia shares are trading lower after the company announced a 1-for-11 reverse stock split.
📉 NegativeBenzinga•Dec 2, 2025, 02:16 PM
MetaVia Announces 1-For-11 Reverse Stock Split Of Its Common Stock, Effective December 4
📉 NegativeBenzinga•Dec 2, 2025, 01:47 PM
MetaVia To Present Positive New Phase 2a Data On Vanoglipel At AASLD The Liver Meeting 2025
📈 PositiveBenzinga•Nov 7, 2025, 01:34 PM
MetaVia Q3 EPS $(0.14) Beats $(0.25) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 01:41 PM
MTVA stock has given up its prior gain. MetaVia shares were trading higher after the company announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor.
➖ NeutralBenzinga•Nov 5, 2025, 07:04 PM
MetaVia shares are trading higher after the company announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor.
📈 PositiveBenzinga•Nov 5, 2025, 03:28 PM
MetaVia To Present New Phase 1 And Pre-clinical Data On DA-1726 In Two Poster Presentations At ObesityWeek 2025; New Phase 1 PK Data Support Once-Weekly Dosing; Clinically Meaningful Weight Loss Observed Without Dose Titration
📈 PositiveBenzinga•Nov 4, 2025, 09:28 PM
MetaVia To Present Vanoglipel Data For MASH At AASLD, Highlighting Hepatoprotective And Metabolic Effects
📈 PositiveBenzinga•Oct 27, 2025, 12:43 PM
MetaVia Shares Resume Trade Following Circuit Breaker Halt
➖ NeutralBenzinga•Sep 15, 2025, 07:12 PM
HC Wainwright & Co. Assumes MetaVia at Buy, Announces Price Target of $12
📈 PositiveBenzinga•Sep 4, 2025, 11:28 AM
Frequently Asked Questions about MTVA
What is MTVA's current stock price?
MetaVia Inc. (MTVA) is currently trading at $8.62 per share. The stock has moved +3.86% today.
What is the analyst price target for MTVA?
No analyst price targets are currently available for this stock.
What sector is MetaVia Inc. in?
MetaVia Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MTVA's market cap?
MetaVia Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does MTVA pay dividends?
No, MetaVia Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCASI
CASI Pharmaceuticals, Inc.
$0.81
Mkt Cap: $0.0B
CLGN
CollPlant Biotechnologies Ltd.
$1.52
Mkt Cap: $0.0B
CLSD
Clearside Biomedical, Inc.
$1.00
Mkt Cap: $0.0B
ENLV
Enlivex Therapeutics Ltd.
$0.83
Mkt Cap: $0.0B
KLTO
Klotho Neurosciences, Inc.
$0.39
Mkt Cap: $0.0B
LSTA
Lisata Therapeutics, Inc.
$2.06
Mkt Cap: $0.0B
NCNA
NuCana plc
$3.56
Mkt Cap: $0.0B
PASG
Passage Bio, Inc.
$9.59
Mkt Cap: $0.0B
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
Mkt Cap: $0.0B
XCUR
Exicure, Inc.
$5.92
Mkt Cap: $0.0B
Explore stocks similar to MTVA for comparison